US EditionBlood Test Detects Early Signs of Alzheimer’s in Middle Age
FINLAND, JUL 14 – Researchers identified blood biomarkers linked to Alzheimer’s risk in 2,051 middle-aged people and their parents, highlighting potential for early detection and targeted prevention.
- A 2025 Finnish study led by University of Turku researcher Suvi Rovio found elevated Alzheimer's-related blood biomarkers in middle-aged adults aged 41-56 and their parents.
- The study built on earlier work showing the APOE ε4 gene raises Alzheimer's risk but found no clear biomarker association with APOE ε4 in middle age, though kidney disease independently linked to higher biomarker levels.
- Researchers observed biomarker concentrations increased with age and showed intergenerational patterns, with higher biomarker levels in parents, especially mothers, correlating with elevated levels in their offspring.
- Suvi Rovio said reliable clinical use requires standardized biomarker reference values across populations and age groups; currently, no single blood test definitively diagnoses Alzheimer's disease.
- The findings suggest blood-based biomarker screening could enable earlier, cost-effective identification of at-risk individuals to target preventive treatments before symptoms emerge.
17 Articles
17 Articles
Six-hour ‘undo’ button: GAI-17 rewinds stroke damage and may beat Alzheimer’s
Stroke kills millions, but Osaka researchers have unveiled GAI-17, a drug that halts toxic GAPDH clumping, slashes brain damage and paralysis in mice—even when given six hours post-stroke—and shows no major side effects, hinting at a single therapy that could also tackle Alzheimer’s and other tough neurological disorders.
Several researches contemplate the analysis of nasal mucosa to diagnose diseases such as lung cancer, Alzheimer's or Parkinson's disease.
P-tau217 and other blood biomarkers of dementia: variation with time of day
Plasma biomarkers of dementia, including phosphorylated tau (p-tau217), offer promise as tools for diagnosis, stratification for clinical trials, monitoring disease progression, and assessing the success of interventions in those living with Alzheimer’s disease. However, currently, it is unknown whether these dementia biomarker levels vary with the time of day, which could have implications for their clinical value. In two protocols, we studied …
Coverage Details
Bias Distribution
- 60% of the sources are Center
To view factuality data please Upgrade to Premium
